← SynDRA
SGX-523
SynDRA canonical compound SYN0024367 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | MET |
|---|
| Mechanism of action | hepatocyte growth factor receptor inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- MET INHIBITOR
- Hepatocyte growth factor receptor inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- MAPK10
- MAPK8
- ABL1
- NQO2
- DYRK1A
- DYRK1B
- PIP4K2C
- MAP3K19
- PEBP1
- PFKP
- PGRMC1
- PHKG1
- PI4KB
- PHKG2
- PDPK1
- PIK3C2B
- PIK3C2G
- PIK3CA
- PDXK
- PASK
- PDGFRB
- PDGFRA
- PCYT1A
- PIK3CD
- PAK6
- PAK5
- PAK4
- PAK3
- PAK2
- PAK1
- PAICS
- OXSR1
- PIK3CB
- PIM3
- PIK3CG
- PLK4
- PRKCD
- PRKCB
- PRKCA
- PRKAR2A
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Cross-references
Synonyms
- SGX 523
- SGX523
- SGX523, SGX-523
- WH8SQN09KJ
- CHEBI:90624
- RefChem:884969
- MET TYROSINE KINASE INHIBITOR SGX523
- BDBM50355498
- UNII-WH8SQN09KJ
- C18H13N7S
- 3dkf
- 3dkg
- MFCD16660190
- MLS006010279
- GTPL5709
- orb1305777
- SCHEMBL4496422
- SCHEMBL29354539
- SCHEMBL30222396
- BDBM60589
- BCZUAADEACICHN-UHFFFAOYSA-N
- GLXC-21110
- GLXC-90292
- HMS3295E13
- HMS3654I04
- EX-A1482
- SGX-523?
- NSC758591
- NSC800884
- s1112
- AKOS025117577
- CCG-264717
- CS-0154
- EBC-222030
- FM32803
- NSC-758591
- NSC-800884
- SB19371
Look up SGX-523 in the interactive SynDRA portal →